Wegovy and Breastfeeding: The Injection and the Tablet Are Not the Same

The fast answer

Wegovy injection does not carry a "do not breastfeed" instruction. Its label says there are no data on semaglutide in human milk, and asks that the benefits of breastfeeding be weighed against your clinical need for the drug — the standard formula for an unstudied medicine, not a prohibition¹.

Wegovy 25 mg tablets do. That label states breastfeeding is not recommended during treatment — and the reason is an ingredient, not the semaglutide¹.

If you have read anywhere that "the Wegovy label advises against breastfeeding," that sentence is true of one formulation and false of the other. It matters, because the label's own fix for the tablet problem is to use the injection.

Some links below go to programs we may earn a referral fee from; it never changes an ordering. See our disclosure.

What each label actually says

Three of the four rows say the same thing. Only the tablet row is different.

The tablet's problem is SNAC, and it is a real one

Salcaprozate sodium (SNAC) is an absorption enhancer that lets a peptide survive the stomach — it is what makes an oral semaglutide possible at all. The Wegovy label's reasoning is specific: SNAC and/or its metabolites are present in human milk, the enzymes that clear SNAC may be less active in infants than in adults, so higher levels could accumulate in a neonate. And then it gives its own remedy — "there are alternative formulations of semaglutide that do not contain SNAC that can be used during lactation"¹.

The NIH's lactation database reaches the same conclusion in one line: "Only injectable forms of semaglutide should be used during breastfeeding."⁴ If needles are the sticking point, the trade-off is worth reading properly — the oral GLP-1 outlook covers what you give up either way.

What the milk studies found

Two independent measurements, both small, both pointing the same direction:

• Semaglutide, injected. Milk from eight lactating women, sampled at 0, 12 and 24 hours after a dose and run on high-resolution liquid chromatography–mass spectrometry. Semaglutide was not detected in any sample. Using the limit of quantification as a worst case, the projected relative infant dose was 1.26% — far below the 10% threshold conventionally treated as reassuring⁵.
• Tirzepatide. The Zepbound label prints its own single-dose lactation study: 11 healthy lactating adults, and the drug was undetectable in 164 of 171 samples. In the remaining seven, the cumulative amount over 28 days came to less than 0.02% of the maternal dose³.

Eight women and eleven women. That is not a safety trial, and neither study followed the infants. Say that out loud in the appointment.

Where the data genuinely run out

Three things are unstudied, and no amount of reading fixes them:

• Milk supply. No label and no trial reports an effect of these drugs on milk production, in either direction. Nobody has looked.
• Long-term infant outcomes. The semaglutide study's authors name this as an open question themselves⁵.
• Maternal nutrition while lactating. Breastfeeding raises energy and fluid needs at the same moment a GLP-1 suppresses appetite. That collision has not been studied either, and it is the one you will feel first — hydration slips fast when you are eating less and feeding a baby. The warning signs are in does Ozempic make your pee smell.

Bring this to the visit

1. 1.Which formulation you are on or being offered — injection or 25 mg tablet. It is the only fork that changes the answer.
2. 2.Your baby's age. A newborn's clearance is the reason the SNAC concern exists at all.
3. 3.How far postpartum you are, and whether restarting can wait.
4. 4.Contraception, if a second pregnancy is anywhere on the horizon — the timing rules differ by drug, and they are in can you take Zepbound while pregnant.

If your prescriber tells you to stop nursing because "the label says so," ask which label. On the injection, it does not.